Abstract

The radiochemistry core provides the radiopharmaceuticals, radiopharmaceutical quality control, metabolite analysis and regulatory documentation required by the projects to fulfill the goals of the research described in this application.
The specific aims are to produce 11C, 18F, 15O and 124I, and to use these radionuclides to make the radiopharmaceuticals: 2-[11C]thymidine; [11C]-verapamil; [11C]-meta-hydroxyephedrine; [11C]-carbon dioxide; [18F]-2-fluoro-2-deoxy-D-glucose; [18F]-fluoromisonidazole; [18F]-fluorothymidine; [18F]-fluoroannexin V; 16-alpha-[18F]-fluoroestradiol; [15O]-water and injectable [124I]-iodide. Robot-assisted and remotely operated syntheses are used to make procedures more convenient and to keep radiation exposure to the chemists as low as reasonably achievable. The radiochemists are responsible for assuring the radiochemical purity and pharmaceutical quality of all products for in vivo studies and for compliance with all regulations regarding radiation and pharmaceutical safety.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
2P01CA042045-17A1
Application #
6984658
Study Section
Subcommittee G - Education (NCI)
Project Start
2004-05-10
Project End
2009-02-28
Budget Start
2004-05-10
Budget End
2005-02-28
Support Year
17
Fiscal Year
2004
Total Cost
$273,388
Indirect Cost

  Institution

Name
University of Washington
Department
Type
DUNS #
605799469
City
Seattle
State
WA
Country
United States
Zip Code
98195

  Publications

Lindner, Jonathan R; Link, Jeanne (2018) Molecular Imaging in Drug Discovery and Development. Circ Cardiovasc Imaging 11:e005355
O'Sullivan, Finbarr; O'Sullivan, Janet N; Huang, Jian et al. (2018) Assessment of a statistical AIF extraction method for dynamic PET studies with 15O water and 18F fluorodeoxyglucose in locally advanced breast cancer patients. J Med Imaging (Bellingham) 5:011010
Linden, Hannah M; Peterson, Lanell M; Fowler, Amy M (2018) Clinical Potential of Estrogen and Progesterone Receptor Imaging. PET Clin 13:415-422
Link, Jeanne M; Krohn, Kenneth A; O'Hara, Matthew J (2017) A simple thick target for production of89Zr using an 11MeV cyclotron. Appl Radiat Isot 122:211-214
Wolsztynski, E; O'Sullivan, F; O'Sullivan, J et al. (2017) Statistical assessment of treatment response in a cancer patient based on pre-therapy and post-therapy FDG-PET scans. Stat Med 36:1172-1200
Kurland, Brenda F; Peterson, Lanell M; Lee, Jean H et al. (2017) Estrogen Receptor Binding (18F-FES PET) and Glycolytic Activity (18F-FDG PET) Predict Progression-Free Survival on Endocrine Therapy in Patients with ER+ Breast Cancer. Clin Cancer Res 23:407-415
Wangerin, Kristen A; Muzi, Mark; Peterson, Lanell M et al. (2017) A virtual clinical trial comparing static versus dynamic PET imaging in measuring response to breast cancer therapy. Phys Med Biol 62:3639-3655
Fowler, Amy M; Clark, Amy S; Katzenellenbogen, John A et al. (2016) Imaging Diagnostic and Therapeutic Targets: Steroid Receptors in Breast Cancer. J Nucl Med 57 Suppl 1:75S-80S
Muzi, Mark; Krohn, Kenneth A (2016) Imaging Hypoxia with ยน?F-Fluoromisonidazole: Challenges in Moving to a More Complicated Analysis. J Nucl Med 57:497-8
Currin, Erin; Peterson, Lanell M; Schubert, Erin K et al. (2016) Temporal Heterogeneity of Estrogen Receptor Expression in Bone-Dominant Breast Cancer: 18F-Fluoroestradiol PET Imaging Shows Return of ER Expression. J Natl Compr Canc Netw 14:144-7

Showing the most recent 10 out of 196 publications